Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose.
Daniele VerittiValentina SaraoFrancesco Di BinPaolo LanzettaPublished in: Pharmaceutics (2023)
Fixed q12-q15 (every 12-15 weeks) 8 mg aflibercept regimens can produce adequate intravitreal VEGF inhibition.